Heparin Use in Daily Hemodialysis
Identifieur interne : 005859 ( Main/Exploration ); précédent : 005858; suivant : 005860Heparin Use in Daily Hemodialysis
Auteurs : J. Hynes [États-Unis] ; T. Mccomb [États-Unis] ; B. Young [États-Unis]Source :
- Hemodialysis International [ 1492-7535 ] ; 2004-01.
Abstract
More frequent dialysis is thought to be associated with increased heparin requirements; however, limited data are available which compare heparin requirements of conventional to daily dialysis. Objectives: To determine differences in heparin dose during conventional thrice‐weekly dialysis (CHD) compared to daily hemodialysis (DHD). Methods: All patients within the daily home hemodialysis at the Northwest Kidney Centers were evaluated for heparin dose both pre‐ and post initiation of daily hemodialysis. Patients on DHD received an initial bolus of heparin, without a continuous heparin drip, and supplemental heparin midway through the dialysis run as needed to maintain adequate activated clotting times (ACTs). CHD patients received a heparin bolus, followed by initiation of heparin drip as needed to maintain adequate ACTs. Results: Of the 1117 patients who dialyze at the NKC, 55% were Caucasian, 21% African‐American, 20% Asian/Pacific Islander, and 35% were of other ethnicity. The majority of patients were greater than 60 years (56%), while 36% ranged from 40–60 years and 13% ranged from 20–40 years. Male patients constituted 54% of patients. Diabetes was the primary cause of renal disease (36%), followed by hypertension (21%) and glomerular disease (18%). Of those patients in the home hemodialysis program (n = 45), 10 patients started daily home hemodialysis using the Aksys daily home hemodialysis system. Of those, the majority was male (100%), Caucasian (78.8%) with an average age of 46.7 ± 18 years. Glomerulonephritis was the primary cause of end‐stage renal disease (40%), while the percentages of other diseases were similar [Alport's syndrome (20%), hypertension (20%) and diabetes (10%)]. Compared to initial DHD heparin requirements (10,111 ± 2219 units), CHD heparin dose requirements (6833 ± 2715 units) were significantly lower (p = 0.045); however, total heparin needs were similar between groups (10,166 ± 4380 units vs. 10,778 ± 2959 units) (p = 0.324). Conclusion: Although patients initiating DHD have greater initial heparin requirements than when on CHD, total heparin doses remain similar to those required on conventional thrice‐weekly hemodialysis. Greater initial heparin doses required during short daily dialysis appear safe compared to those of conventional dialysis.
Url:
DOI: 10.1111/j.1492-7535.2004.0085al.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001498
- to stream Istex, to step Curation: 001498
- to stream Istex, to step Checkpoint: 001F38
- to stream Main, to step Merge: 005D05
- to stream Main, to step Curation: 005859
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heparin Use in Daily Hemodialysis</title><author><name sortKey="Hynes, J" sort="Hynes, J" uniqKey="Hynes J" first="J." last="Hynes">J. Hynes</name></author><author><name sortKey="Mccomb, T" sort="Mccomb, T" uniqKey="Mccomb T" first="T." last="Mccomb">T. Mccomb</name></author><author><name sortKey="Young, B" sort="Young, B" uniqKey="Young B" first="B." last="Young">B. Young</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7A2F5D52283BEE14D679E36FF4D7E19787FECBD3</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1492-7535.2004.0085al.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-XV1W5VTL-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001498</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001498</idno><idno type="wicri:Area/Istex/Curation">001498</idno><idno type="wicri:Area/Istex/Checkpoint">001F38</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F38</idno><idno type="wicri:doubleKey">1492-7535:2004:Hynes J:heparin:use:in</idno><idno type="wicri:Area/Main/Merge">005D05</idno><idno type="wicri:Area/Main/Curation">005859</idno><idno type="wicri:Area/Main/Exploration">005859</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Heparin Use in Daily Hemodialysis</title><author><name sortKey="Hynes, J" sort="Hynes, J" uniqKey="Hynes J" first="J." last="Hynes">J. Hynes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Home Hemodialysis Unit, Northwest Kidney Centers, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Mccomb, T" sort="Mccomb, T" uniqKey="Mccomb T" first="T." last="Mccomb">T. Mccomb</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Home Hemodialysis Unit, Northwest Kidney Centers, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Young, B" sort="Young, B" uniqKey="Young B" first="B." last="Young">B. Young</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Home Hemodialysis Unit, Northwest Kidney Centers, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Hemodialysis International</title><title level="j" type="alt">HEMODIALYSIS INTERNATIONAL</title><idno type="ISSN">1492-7535</idno><idno type="eISSN">1542-4758</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="92">92</biblScope><biblScope unit="page" to="93">93</biblScope><biblScope unit="page-count">100</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-01">2004-01</date></imprint><idno type="ISSN">1492-7535</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1492-7535</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">More frequent dialysis is thought to be associated with increased heparin requirements; however, limited data are available which compare heparin requirements of conventional to daily dialysis. Objectives: To determine differences in heparin dose during conventional thrice‐weekly dialysis (CHD) compared to daily hemodialysis (DHD). Methods: All patients within the daily home hemodialysis at the Northwest Kidney Centers were evaluated for heparin dose both pre‐ and post initiation of daily hemodialysis. Patients on DHD received an initial bolus of heparin, without a continuous heparin drip, and supplemental heparin midway through the dialysis run as needed to maintain adequate activated clotting times (ACTs). CHD patients received a heparin bolus, followed by initiation of heparin drip as needed to maintain adequate ACTs. Results: Of the 1117 patients who dialyze at the NKC, 55% were Caucasian, 21% African‐American, 20% Asian/Pacific Islander, and 35% were of other ethnicity. The majority of patients were greater than 60 years (56%), while 36% ranged from 40–60 years and 13% ranged from 20–40 years. Male patients constituted 54% of patients. Diabetes was the primary cause of renal disease (36%), followed by hypertension (21%) and glomerular disease (18%). Of those patients in the home hemodialysis program (n = 45), 10 patients started daily home hemodialysis using the Aksys daily home hemodialysis system. Of those, the majority was male (100%), Caucasian (78.8%) with an average age of 46.7 ± 18 years. Glomerulonephritis was the primary cause of end‐stage renal disease (40%), while the percentages of other diseases were similar [Alport's syndrome (20%), hypertension (20%) and diabetes (10%)]. Compared to initial DHD heparin requirements (10,111 ± 2219 units), CHD heparin dose requirements (6833 ± 2715 units) were significantly lower (p = 0.045); however, total heparin needs were similar between groups (10,166 ± 4380 units vs. 10,778 ± 2959 units) (p = 0.324). Conclusion: Although patients initiating DHD have greater initial heparin requirements than when on CHD, total heparin doses remain similar to those required on conventional thrice‐weekly hemodialysis. Greater initial heparin doses required during short daily dialysis appear safe compared to those of conventional dialysis.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Hynes, J" sort="Hynes, J" uniqKey="Hynes J" first="J." last="Hynes">J. Hynes</name></region><name sortKey="Mccomb, T" sort="Mccomb, T" uniqKey="Mccomb T" first="T." last="Mccomb">T. Mccomb</name><name sortKey="Young, B" sort="Young, B" uniqKey="Young B" first="B." last="Young">B. Young</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005859 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005859 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7A2F5D52283BEE14D679E36FF4D7E19787FECBD3
|texte= Heparin Use in Daily Hemodialysis
}}
| This area was generated with Dilib version V0.6.33. |  |